The Enhanced Harm Reduction Working Group is a consortium of scientific experts, academics, policy makers, treatment providers and advocacy groups, co-operating to reduce the harms of drug use.


Drug Science believes that there is good real-world evidence for the positive effects of Supervised Injecting Facilities (SIFs) across the globe.

SIFs are known by many names including Supervised Injection Facilities, Overdose Prevention Centres, and Drug Consumption Rooms. There are subtle nuances between these three amenities, however, their function is to provide safe spaces for people to consume controlled drugs under the supervision of people who can save lives if overdoses occur.

Drug Science believes that access to sterile equipment, overdose prevention and treatment benefits both people who use drugs and the wider community.

Drug Science deems it important to develop the evidence base for reducing drug-related harms by piloting SIFs in the UK. This collaborative initiative will evaluate whether establishing SIFs would; prove to be cost effective, reduce crime, improve public health, lessen drug litter, and increase engagement in treatment services.

The Enhanced Harm Reduction  Working Group encourages the use of a participatory development approach in the design and development of SIFs. Consulting people who will be the end users of the SIF in the design, development and implementation is key to ensure the model is fit for purpose, community friendly, and holds the confidence of the local drug using community. People who use drugs are sadly familiar with experiencing discrimination in health and social care settings. As such, those developing new services need to actively demonstrate their commitment to a non-judgemental and rights-based approach and participatory development is a good starting point. When the community owns and supports the SIF then this will help with client recruitment, quality management and advocacy.

The Enhanced Harm Reduction Working Group (EHRWG) is a consortium of Drug Science experts, leading academics, researchers, people who use drugs, and policy specialists. The EHRWGwill work with several partners to establish pilot SIFs for evaluation. Furthermore, the group will inform legal reform and produce recommendations to enable the development of the evidence base on SIFs. In addition to this, it will collate and communicate the evidence base on the role of SIFs in reducing drug-related harm.


Academic Experts

Prof Alex Stevens (Chair)

Professor of Criminal Justice

Prof David Nutt

Professor of Neuro-psychopharmacology

Prof Fiona Measham

Chair in Criminology

Prof Lindsay Forbes

Professor of Public Health

Prof Charlie Lloyd

Professor of Social Policy and Criminal Justice

Dr Euan Lawson

Editor of the British Journal of General Practice

Dr Gillian Shorter

Reader in Psychology

Dr Tim Williams

Consultant Addiction Psychiatrist

Dr Magdalena Harris

Associate Professor in the Sociology of Health

Roz Gittins

Drug Science Scientific Committee

Lucy Strang

Research Associate, Kings College London

Dr Andy Mcauley

Reader in Public Health,
Glasgow Caledonian University

Policy Specialists

Kirstie Douse

Head of Legal Services, Release

Mat Southwell

Associate Consultant, IDPC

Colleen Daniels

Deputy Director, Harm Reduction International

Jason Kew

Detective Chief Inspector, Thames Valley Police

Martin Powell

Head of Partnerships, Transform

Kirsten Horsburgh

Strategy Coordinator, Scottish Drugs Forum

Treatment Provider Representatives

Claire James

Deputy Director of Clinical Practice, Change Grow Live

Felicity Simpkin

Associate Director, With You

Martin Blakebrough

CEO, Kaleidoscope

Charlie Mack

CEO, Cranstoun

Peter Krykant


Lee Wilson

Regional Director, Humankind

Danny Ahmed

Clinical Partner, Foundations

Treatment Providers

The Enhanced Harm Reduction Working Group is supported by treatment providers to ensure that the stakeholders who would be delivering these services are consulted throughout.